Michael F. Huang, Senior Vice President of Clinical Development at Soleno Therapeutics Inc (NASDAQ:SLNO), disposed of 6,582 shares of the company's common stock on March 27, 2026, according to a Securities and Exchange Commission filing.
The sales were carried out in three separate trades, each recorded with transaction code "S." Execution prices for the blocks ranged from $30.037 to $31.7187 per share, producing aggregate proceeds of $200,364. The company filing states these shares were sold specifically to satisfy tax withholding obligations associated with the vesting of restricted stock units.
After these transactions, Huang holds 39,823 shares of Soleno Therapeutics directly.
The insider sale coincides with a period of weakness in Soleno's market valuation. SLNO shares were trading at $33.48 at the time of reporting, close to their 52-week low of $29.43, and the stock has declined roughly 44% over the prior six months.
Despite recent share-price pressure, third-party analysis noted in the filing suggests the stock may be trading below its Fair Value. That analysis, identified as InvestingPro, reports a strong buy consensus among analysts with price targets spanning from $60 to $145. Investors are directed to a Pro Research Report for more detailed coverage, which the filing indicates is one of more than 1,400 such reports available for U.S. equities.
Operationally, Soleno released fourth-quarter 2025 financial results that exceeded Street expectations. The company reported earnings per share of $0.80 versus a consensus forecast of $0.61, and revenue of $91.7 million compared with an anticipated $82.45 million.
Management changes are also underway. Soleno has appointed Jennifer Fulk as its new Chief Financial Officer, with the appointment to take effect by the end of the first quarter. She will succeed James Mackaness, who will remain involved as a consultant through the end of 2026 to support the transition.
Following the quarter, two sell-side firms adjusted their valuations of Soleno. H.C. Wainwright reduced its price target to $100 from $120 while retaining a Buy rating. Oppenheimer lowered its target to $80 from $110 and maintained an Outperform rating. The filing states both firms made these adjustments based on the company’s recent performance and prevailing market conditions.
Separately, Soleno amended its corporate bylaws to reflect updates to governance and legal provisions, including changes stemming from Delaware law. The company characterized these bylaw amendments as part of ongoing efforts to adapt to market dynamics and strengthen corporate governance.
Summary of the situation
- Michael F. Huang sold 6,582 shares on March 27, 2026 to cover tax withholding related to vested restricted stock units, totaling $200,364.
- Huang retains direct ownership of 39,823 Soleno shares following the trades.
- Soleno posted stronger-than-expected Q4 2025 results and announced a CFO transition, while analysts trimmed but maintained generally favorable ratings and price targets.
Context and market indicators
The insider sale took place against a backdrop of recent share-price weakness and divergent signals from corporate results and analyst adjustments. The company’s fourth-quarter performance beat expectations on both EPS and revenue, yet the stock has moved lower over the past six months. At the same time, the firm’s governance documents were updated and a new CFO appointment was announced, with the outgoing CFO staying on as a consultant through 2026.